GlaxoSmithKline is expected by analysts to report a fall in revenue of more than £100 million after a collapse in sales of Avandia, its diabetes medicine, which has been linked to an increased risk of heart attacks and strokes.
Britain’s biggest drugmaker is due to unveil its interim results tomorrow, its first quarterly figures since a controversial study by leading cardiologists claimed that the drug raised the risk of heart attack by 43 per cent.
More at The Times
1 comment:
Why are analysts wrong almost all the time?
Post a Comment